


Valecobulin

Cat. No.:	HY-13598
CAS No.:	1188371-47-2
Molecular Formula:	C ₂₆ H ₂₈ N ₆ O ₅ S
Molecular Weight:	536.6
Target:	Microtubule/Tubulin
Pathway:	Cell Cycle/DNA Damage; Cytoskeleton
Storage:	Please store the product under the recommended conditions in the COA.



BIOLOGICAL ACTIVITY

Description	Valecobulin (CKD516), a valine prodrug of (S516) and a vascular disrupting agent (VDA), is a potent beta-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors ^{[1][2]} .								
IC₅₀ & Target	Beta-tubulin polymerization ^[1] .								
In Vivo	<p>The size change of the tumor in VX2 liver tumor-bearing rabbits is significantly smaller in the Valecobulin (CKD516)(5, 9, or 12 mg/m², i.v.)- treated group than in control group^[2].</p> <table border="1"> <tr> <td>Animal Model:</td> <td>VX2 liver tumor-bearing rabbits (Male New Zealand White rabbits weighing between 2.5 and 3.5 kg)^[2].</td> </tr> <tr> <td>Dosage:</td> <td>Dissolved in 5 mL of saline at a dose of 5, 9, or 12 mg/m² of body surface area.</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection once.</td> </tr> <tr> <td>Result:</td> <td>The size change of the tumors was significantly smaller in the treated group than in control group.</td> </tr> </table>	Animal Model:	VX2 liver tumor-bearing rabbits (Male New Zealand White rabbits weighing between 2.5 and 3.5 kg) ^[2] .	Dosage:	Dissolved in 5 mL of saline at a dose of 5, 9, or 12 mg/m ² of body surface area.	Administration:	Intravenous injection once.	Result:	The size change of the tumors was significantly smaller in the treated group than in control group.
Animal Model:	VX2 liver tumor-bearing rabbits (Male New Zealand White rabbits weighing between 2.5 and 3.5 kg) ^[2] .								
Dosage:	Dissolved in 5 mL of saline at a dose of 5, 9, or 12 mg/m ² of body surface area.								
Administration:	Intravenous injection once.								
Result:	The size change of the tumors was significantly smaller in the treated group than in control group.								

REFERENCES

[1]. Lee J, et al. Identification of CKD-516: a potent tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. *J Med Chem.* 2010 Sep 9;53(17):6337-54.

[2]. Joo I, et al. Intravoxel incoherent motion diffusion-weighted MR imaging for monitoring the therapeutic efficacy of the vascular disrupting agent CKD-516 in rabbit VX2 liver tumors. *Radiology.* 2014 Aug;272(2):417-26.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA